GB1096951A - Vaccines comprising inactivated myxoviruses - Google Patents

Vaccines comprising inactivated myxoviruses

Info

Publication number
GB1096951A
GB1096951A GB11807/64A GB1180764A GB1096951A GB 1096951 A GB1096951 A GB 1096951A GB 11807/64 A GB11807/64 A GB 11807/64A GB 1180764 A GB1180764 A GB 1180764A GB 1096951 A GB1096951 A GB 1096951A
Authority
GB
United Kingdom
Prior art keywords
virus
inactivated
vaccine
ccl2
myxoviruses
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB11807/64A
Inventor
Alexander David Kanarek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellcome Foundation Ltd
Original Assignee
Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to BE661402D priority Critical patent/BE661402A/xx
Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd
Priority to GB11807/64A priority patent/GB1096951A/en
Priority to DK143165AA priority patent/DK111007B/en
Priority to FR1587316D priority patent/FR1587316A/fr
Priority to IL23187A priority patent/IL23187A/en
Priority to CH393965A priority patent/CH471896A/en
Priority to NL656503607A priority patent/NL149377B/en
Publication of GB1096951A publication Critical patent/GB1096951A/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/20—Rubella virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16161—Methods of inactivation or attenuation
    • C12N2760/16163—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16261—Methods of inactivation or attenuation
    • C12N2760/16263—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18461—Methods of inactivation or attenuation
    • C12N2760/18463—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18811—Sendai virus
    • C12N2760/18861—Methods of inactivation or attenuation
    • C12N2760/18863—Methods of inactivation or attenuation by chemical treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

A vaccine comprises antigens derived from myxoviruses inactivated by a process which comprises contacting the viruses in aqueous suspension at pH 6-8 in the presence of at least about 0.05% w/v. of a non-ionic hydrophilic surface active agent with a fully or partially chlorinated, or chlorinated and fluorinated C1-5 hydrocarbon, other than CHCl3, which is liquid at 15-25 DEG C. Specified myxoviruses are M. influenzae-A, B, and C, M. parainfluenzae-1, 2, 3, and 4, M. multiformae, M. pestigalli, M. parotidis, measles virus, distemper virus, rinder-pest virus, and respiratory syncytical virus. The non-ionic surface active agent may be a polyoxyethylene sorbitan mono-oleate or another polyoxyalkylene ether of partial lauric, palmitic, stearic or oleic acid esters. Specified halogenated hydrocarbons are CCl4, CHCl= CCl2, CCl2=CCl2, CFCl2.CClF2, CCl3.CH2.CCl3 and Cl2.C=C.Cl-C.Cl=C.Cl2. Any strain of the selected virus may be used. The virus may be cultivated on chick embryo or monkey kidney tissue cultures, stable diploid cell line culture or, where appropriate, in embryonated hens' eggs. The tissue culture fluid or harvested allantoic fluid is clarified and the virus therein is inactivated by contact with the above organic solvent. The organic solvent is subsequently removed, leaving an aqueous suspension containing inactivated fragmented virus particles, i.e. the primary vaccine. Stabilizers, e.g. polyvinyl pyrrolidone or dextran, and protamine sulphate, may be added. The primary vaccine may be purified or concentrated, e.g. by adsorbing the fragments of inactivated virus on to aluminium oxide or hydroxide or an aluminium salt (e.g. phosphate or alum) substantially isoluble at pH 6-8. Alternatively, a soluble aluminium salt may be added in solution to the primary vaccine and alum precipitated therefrom by the addition of an appropriate potassium salt and adjustment of pH to the required value. The adsorbate may be separated and resuspended in a saline solution buffered to pH 6.0-8.0. The purified or concentrated vaccine may be mixed with other vaccines, or the aluminium salt, oxide or hydroxide may be used to adsorb other materials having different antigenicity.
GB11807/64A 1964-03-20 1964-03-20 Vaccines comprising inactivated myxoviruses Expired GB1096951A (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
BE661402D BE661402A (en) 1964-03-20
GB11807/64A GB1096951A (en) 1964-03-20 1964-03-20 Vaccines comprising inactivated myxoviruses
DK143165AA DK111007B (en) 1964-03-20 1965-03-19 Procedure for inactivating myxovirus.
FR1587316D FR1587316A (en) 1964-03-20 1965-03-19
IL23187A IL23187A (en) 1964-03-20 1965-03-19 Production of vaccines
CH393965A CH471896A (en) 1964-03-20 1965-03-22 Method for inactivating myxoviruses
NL656503607A NL149377B (en) 1964-03-20 1965-03-22 PROCEDURE FOR PREPARING AN INACTIVATED MYXOVIRUS.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB11807/64A GB1096951A (en) 1964-03-20 1964-03-20 Vaccines comprising inactivated myxoviruses

Publications (1)

Publication Number Publication Date
GB1096951A true GB1096951A (en) 1967-12-29

Family

ID=9993058

Family Applications (1)

Application Number Title Priority Date Filing Date
GB11807/64A Expired GB1096951A (en) 1964-03-20 1964-03-20 Vaccines comprising inactivated myxoviruses

Country Status (7)

Country Link
BE (1) BE661402A (en)
CH (1) CH471896A (en)
DK (1) DK111007B (en)
FR (1) FR1587316A (en)
GB (1) GB1096951A (en)
IL (1) IL23187A (en)
NL (1) NL149377B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4663161A (en) * 1985-04-22 1987-05-05 Mannino Raphael J Liposome methods and compositions
US4871488A (en) * 1985-04-22 1989-10-03 Albany Medical College Of Union University Reconstituting viral glycoproteins into large phospholipid vesicles

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1292197A (en) * 1969-05-16 1972-10-11 American Home Prod Method for the disruption of viruses
FR2475572A1 (en) * 1980-02-11 1981-08-14 Pasteur Institut PROCESS FOR OBTAINING LIPID ENVELOPE VIRUS FRAGMENTS, PARTICULARLY ANTIGENS USED AS VACCINES, PRODUCTS OBTAINED AND APPLICATIONS
FR2483779A1 (en) 1980-06-05 1981-12-11 Synthelabo PROCESS FOR ISOLATING VIRAL GLYCOPROTETIC ANTIGENS AND APPLICATION THEREOF TO VACCINE PREPARATION
US4909940A (en) * 1987-12-30 1990-03-20 New York Blood Center, Inc. Extraction of process chemicals from labile biological mixtures with organic alcohols or with halogenated hydrocarbons
GB9018690D0 (en) * 1990-08-24 1990-10-10 Wellcome Found Vaccines

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4663161A (en) * 1985-04-22 1987-05-05 Mannino Raphael J Liposome methods and compositions
US4871488A (en) * 1985-04-22 1989-10-03 Albany Medical College Of Union University Reconstituting viral glycoproteins into large phospholipid vesicles

Also Published As

Publication number Publication date
BE661402A (en)
IL23187A (en) 1969-01-29
CH471896A (en) 1969-04-30
FR1587316A (en) 1970-03-20
DK111007B (en) 1968-04-29
NL6503607A (en) 1965-09-21
NL149377B (en) 1976-05-17

Similar Documents

Publication Publication Date Title
Melnick et al. A new member of the herpesvirus group isolated from South American marmosets
US4188375A (en) Process for the preparation of vaccines
US3699222A (en) Production of viral interfering substances
GB1096951A (en) Vaccines comprising inactivated myxoviruses
Bachmayer et al. Preparation and properties of a novel influenza subunit vaccine
CN113994925B (en) Rotavirus challenge animal model and establishment method thereof
Beard et al. Preparation of Newcastle disease virus hemagglutination-inhibition test antigen
Craighead et al. Encephalomyocarditis virus hemagglutination-inhibition test using antigens prepared in HeLa cell cultures
Kono et al. An epidemic of Getah virus infection among racehorses: properties of the virus
US3847737A (en) Inactivation of myxoviruses and method of preparing a vaccine therefrom
CN113975412B (en) Method for evaluating effectiveness of rotavirus vaccine
US3981772A (en) Method of attenuating viruses with simultaneous stabilization of their antigens using selected aminomethylol compounds
CN103110943B (en) Novel vaccine adjuvant capable of replacing aluminum hydroxide
CS199569B2 (en) Method of producing vaccine against influenza
DE2452919C3 (en) Process for the preparation of inactivated vaccines against viral diseases
Hoyle et al. Further studies of complement-fixation in influenza: Antigen production in egg-membrane culture and the occurrence of a zone phenomenon
Laver et al. Preparation and immunogenicity of a purified influenza virus haemagglutinin and neuraminidase subunit vaccine
WO2001009290A2 (en) Avian infectious bronchitis virus serotype
US3629413A (en) Polyvalent bovine vaccines and methods of making and using same
CA1214724A (en) Vaccine for bluetongue disease employing platinum compounds
Polley et al. THE USE OF BETA-PROPIOLACTONE FOR THE PREPARATION OF VIRUS VACCINES: I. SELECTION OF REACTION CONDITIONS
KR920010872B1 (en) Preparing vaccine against herpes simplex virus
Shah et al. Hemagglutination with simian papovavirus SA12
GB953992A (en) Vaccine products and method of preparing same
White The position of Taylor's 1233 strain of virus in the human red cell receptor gradient